747 related articles for article (PubMed ID: 25775034)
1. Gut microbiota in multiple sclerosis: possible influence of immunomodulators.
Cantarel BL; Waubant E; Chehoud C; Kuczynski J; DeSantis TZ; Warrington J; Venkatesan A; Fraser CM; Mowry EM
J Investig Med; 2015 Jun; 63(5):729-34. PubMed ID: 25775034
[TBL] [Abstract][Full Text] [Related]
2. Disease-modifying therapies alter gut microbial composition in MS.
Katz Sand I; Zhu Y; Ntranos A; Clemente JC; Cekanaviciute E; Brandstadter R; Crabtree-Hartman E; Singh S; Bencosme Y; Debelius J; Knight R; Cree BAC; Baranzini SE; Casaccia P
Neurol Neuroimmunol Neuroinflamm; 2019 Jan; 6(1):e517. PubMed ID: 30568995
[TBL] [Abstract][Full Text] [Related]
3. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
[TBL] [Abstract][Full Text] [Related]
4. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group.
Johnson KP; Brooks BR; Ford CC; Goodman A; Guarnaccia J; Lisak RP; Myers LW; Panitch HS; Pruitt A; Rose JW; Kachuck N; Wolinsky JS
Mult Scler; 2000 Aug; 6(4):255-66. PubMed ID: 10962546
[TBL] [Abstract][Full Text] [Related]
5. Bolus Weekly Vitamin D3 Supplementation Impacts Gut and Airway Microbiota in Adults With Cystic Fibrosis: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial.
Kanhere M; He J; Chassaing B; Ziegler TR; Alvarez JA; Ivie EA; Hao L; Hanfelt J; Gewirtz AT; Tangpricha V
J Clin Endocrinol Metab; 2018 Feb; 103(2):564-574. PubMed ID: 29161417
[TBL] [Abstract][Full Text] [Related]
6. Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.
Metz LM; Li D; Traboulsee A; Myles ML; Duquette P; Godin J; Constantin M; Yong VW;
Mult Scler; 2009 Oct; 15(10):1183-94. PubMed ID: 19776092
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of immunomodulatory therapy with interferon-β or glatiramer acetate on multiple sclerosis-associated uveitis.
Velazquez-Villoria D; Macia-Badia C; Segura-García A; Pastor Idoate S; Arcos-Algaba G; Velez-Escola L; García-Arumí J
Arch Soc Esp Oftalmol; 2017 Jun; 92(6):273-279. PubMed ID: 28188020
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis.
Kalincik T; Jokubaitis V; Izquierdo G; Duquette P; Girard M; Grammond P; Lugaresi A; Oreja-Guevara C; Bergamaschi R; Hupperts R; Grand'Maison F; Pucci E; Van Pesch V; Boz C; Iuliano G; Fernandez-Bolanos R; Flechter S; Spitaleri D; Cristiano E; Verheul F; Lechner-Scott J; Amato MP; Cabrera-Gomez JA; Saladino ML; Slee M; Moore F; Gray O; Paine M; Barnett M; Havrdova E; Horakova D; Spelman T; Trojano M; Butzkueven H;
Mult Scler; 2015 Aug; 21(9):1159-71. PubMed ID: 25480857
[TBL] [Abstract][Full Text] [Related]
9. The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis.
Zivadinov R; Dwyer MG; Ramasamy DP; Davis MD; Steinerman JR; Khan O
J Neuroimaging; 2015; 25(6):989-95. PubMed ID: 26394270
[TBL] [Abstract][Full Text] [Related]
10. Benefit of endermology on indurations and panniculitis/lipoatrophy during relapsing-remitting multiple sclerosis long-term treatment with glatiramer acetate.
Márquez-Rebollo C; Vergara-Carrasco L; Díaz-Navarro R; Rubio-Fernández D; Francoli-Martínez P; Sánchez-De la Rosa R
Adv Ther; 2014 Aug; 31(8):904-14. PubMed ID: 25047757
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Various Doses of Oral Vitamin D
Charoenngam N; Shirvani A; Kalajian TA; Song A; Holick MF
Anticancer Res; 2020 Jan; 40(1):551-556. PubMed ID: 31892611
[TBL] [Abstract][Full Text] [Related]
12. Immune regulatory effects of high dose vitamin D
Muris AH; Smolders J; Rolf L; Thewissen M; Hupperts R; Damoiseaux J;
J Neuroimmunol; 2016 Nov; 300():47-56. PubMed ID: 27806875
[TBL] [Abstract][Full Text] [Related]
13. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
[TBL] [Abstract][Full Text] [Related]
14. Predictive cytokine biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis.
Valenzuela RM; Kaufman M; Balashov KE; Ito K; Buyske S; Dhib-Jalbut S
J Neuroimmunol; 2016 Nov; 300():59-65. PubMed ID: 27390072
[TBL] [Abstract][Full Text] [Related]
15. The effects of fatigue, depression and the level of disability on the health-related quality of life of glatiramer acetate-treated relapsing-remitting patients with multiple sclerosis in Hungary.
Fricska-Nagy Z; Füvesi J; Rózsa C; Komoly S; Jakab G; Csépány T; Jobbágy Z; Lencsés G; Vécsei L; Bencsik K
Mult Scler Relat Disord; 2016 May; 7():26-32. PubMed ID: 27237753
[TBL] [Abstract][Full Text] [Related]
16. Erythroblastaemia in natalizumab-treated patients with multiple sclerosis.
La Gioia S; Seghezzi M; Barcella V; Dominoni P; Mecca T; Frigeni B; Conti MZ; Vedovello M; Vidali M; Rottoli M; Buoro S
Mult Scler Relat Disord; 2016 Jul; 8():141-4. PubMed ID: 27456890
[TBL] [Abstract][Full Text] [Related]
17. Autoimmune hyperthyroidism in multiple sclerosis under treatment with glatiramer acetate--a case report.
Heesen C; Gbadamosi J; Schoser BG; Pöhlau D
Eur J Neurol; 2001 Mar; 8(2):199. PubMed ID: 11285002
[No Abstract] [Full Text] [Related]
18. Tolerability and Safety of Combined Glatiramer Acetate and N-Acetylcysteine in Relapsing-Remitting Multiple Sclerosis.
Schipper HM; Arnold D; GrandʼMaison F; Melmed C; Moore F; Levental M; Su H; Constantin M; Stril JL; Godin J
Clin Neuropharmacol; 2015; 38(4):127-31. PubMed ID: 26166235
[TBL] [Abstract][Full Text] [Related]
19. [Glatiramer acetate (Copaxone) influence on different stages of multiple sclerosis pathogenesis].
Shmidt TE; Zhuchenko TD; Iakhno NN
Zh Nevrol Psikhiatr Im S S Korsakova; 2003; (Spec No 2):79-82. PubMed ID: 12938640
[TBL] [Abstract][Full Text] [Related]
20. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
O'Connor P; Filippi M; Arnason B; Comi G; Cook S; Goodin D; Hartung HP; Jeffery D; Kappos L; Boateng F; Filippov V; Groth M; Knappertz V; Kraus C; Sandbrink R; Pohl C; Bogumil T; ; O'Connor P; Filippi M; Arnason B; Cook S; Goodin D; Hartung HP; Kappos L; Jeffery D; Comi G
Lancet Neurol; 2009 Oct; 8(10):889-97. PubMed ID: 19729344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
